This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
ΑMT: Difference between revisions
>Josikins m Text replacement - "*'''Effect::Spontaneous tactile sensations'''" to "*'''Effect::Spontaneous physical sensations'''" |
>Isaak Grammatics |
||
| (35 intermediate revisions by 16 users not shown) | |||
| Line 1: | Line 1: | ||
{{SummarySheet}} | |||
{{SubstanceBox/AMT}} | {{SubstanceBox/AMT}} | ||
'''α-Methyltryptamine''' (also known as '''Indopan''' and commonly as '''αMT''' or '''aMT''') is a lesser-known [[psychoactive class::entactogen]] substance of the [[chemical class::tryptamine]] class.<ref name="TiHKAL">{{cite book|title=TiHKAL: The Continuation|title-link=TiHKAL|last1=Shulgin|first1=Alexander|last2=Shulgin|first2=Ann|author-link1=Alexander Shulgin|year=1997|publisher=Transform Press|location=United States|isbn=0-9630096-9-9|oclc=38503252|chapter-url=http://www.erowid.org/library/books_online/tihkal/tihkal48.shtml|chapter=#48. a-MT}}</ref> | |||
Erowid has received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) αMT ingestion."<ref name="amt">AMT (Alphamethyltryptamine, IT-290) Fatalities / Deaths | αMT was originally developed by Upjohn in the 1960s.<ref>{{cite web|title=US Patent 3296072 - Method of Treating Mental Depression|url=https://patents.google.com/patent/US3296072/en|access-date=July 18, 2020|website=Google Patents}}</ref> It was briefly used in the Soviet Union as an [[antidepressant]] under the trade name '''Indopan'''.<ref name="TiHKAL"></ref><ref name="Barceloux2012">{{cite book|author=Donald G. Barceloux|title=Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants|url=https://books.google.com/books?id=OWFiVaDZnkQC&pg=PA196|date=March 20, 2012|publisher=John Wiley & Sons|isbn=978-0-471-72760-6|pages=196–}}</ref><ref name="Iversen2013">{{cite book|author=Leslie Iversen|title=Handbook of Psychopharmacology: Volume 14 Affective Disorders: Drug Actions in Animals and Man|url=https://books.google.com/books?id=ogXrBwAAQBAJ&pg=PA132|date=November 11, 2013|publisher=Springer Science & Business Media|isbn=978-1-4613-4045-4|pages=132–}}</ref><ref name="AcademicPress2013">{{cite book|title=Biological Research on Addiction: Comprehensive Addictive Behaviors and Disorders|url=https://books.google.com/books?id=ZUeCgcrNjOUC&pg=PA632|date=17 May 2013|publisher=Academic Press|isbn=978-0-12-398360-2|pages=632–}}</ref> | ||
Indopan was prescribed in 5-10 mg doses, which is significantly lower than the dose used for recreational effects. | |||
Erowid has received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) αMT ingestion."<ref name="amt">{{cite web|title=AMT (Alphamethyltryptamine, IT-290) - Fatalities / Deaths|publisher=Erowid|url=https://www.erowid.org/chemicals/amt/amt_death.shtml|access-date=July 18, 2020}}</ref> | |||
There were 22 deaths linked to αMT in England and Wales where the drug became popular as a legal high from 2012 until it was banned in early 2015.<ref>{{cite web|url=https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsrelatedtodrugpoisoningenglandandwalesreferencetable|title=Deaths related to drug poisoning, England and Wales|date=August 15, 2019|access-date=July 18, 2020|publisher=Office for National Statistics}}</ref> | |||
Limited data exists about the pharmacological properties, metabolism, and toxicity of aMT, and it has a limited history of non-medical human use. | |||
It is highly advised to use [[harm reduction practices]] if using this substance. | |||
==Chemistry== | ==Chemistry== | ||
αMT, or α-Methyltryptamine is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. AMT is substituted at the alpha carbon R<sub>α</sub> of its tryptamine backbone with a methyl group. | |||
αMT, or α-Methyltryptamine is a synthetic indole alkaloid molecule of the [[tryptamine]] class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R<sub>3</sub> to an amino group via an ethyl side chain. AMT is substituted at the alpha carbon R<sub>α</sub> of its tryptamine backbone with a methyl group. AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers. | |||
AMT is found in freebase form as a racemate of its (R-) and (S-) enantiomers. | |||
==Pharmacology== | ==Pharmacology== | ||
{{Further|Serotonergic psychedelic}} | {{Further|Serotonergic psychedelic}} | ||
αMT acts as a relatively balanced reuptake inhibitor and releasing agent of the main three monoamines; serotonin, norepinephrine, and dopamine,<ref>{{cite journal | vauthors=((Nagai, F.)), ((Nonaka, R.)), ((Satoh Hisashi Kamimura, K.)) | journal=European Journal of Pharmacology | title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | volume=559 | issue=2–3 | pages=132–137 | date= March 2007 | url=https://linkinghub.elsevier.com/retrieve/pii/S0014299906013811 | issn=00142999 | doi=10.1016/j.ejphar.2006.11.075}}</ref> and as a non-selective serotonin receptor agonist.<ref>{{cite journal | vauthors=((Nonaka, R.)), ((Nagai, F.)), ((Ogata, A.)), ((Satoh, K.)) | journal=Biological and Pharmaceutical Bulletin | title=In Vitro Screening of Psychoactive Drugs by [35S]GTP.GAMMA.S Binding in Rat Brain Membranes | volume=30 | issue=12 | pages=2328–2333 | date= 2007 | url=http://www.jstage.jst.go.jp/article/bpb/30/12/30_12_2328/_article | issn=0918-6158 | doi=10.1248/bpb.30.2328}}</ref> | |||
αMT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]. | αMT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] as a [[Agonist#Agonists|partial agonist]]. | ||
αMT also acts as a [[releasing agent]] of [[serotonin]], [[noradrenaline]], and [[dopamine]].<ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | | αMT also acts as a [[releasing agent]] of [[serotonin]], [[noradrenaline]], and [[dopamine]].<ref>{{cite journal|title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain|last1=Nagai|first1=F.|last2=Nonaka|first2=R.|last3=Kamimura|first3=K. S. H.|doi=10.1016/j.ejphar.2006.11.075|date=March 22, 2007|pages=132-137|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459|pmid= 17223101|issue=2-3|volume=559}}</ref><ref>{{cite journal|last2=Nagai|first2=F.|last1=Nonaka|first1=R.|last3=Ogata|first3=A.|last4=Satoh|first4=K.|title=''In Vitro'' Screening of Psychoactive Drugs by [<sup>35</sup>S]GTPγS Binding in Rat Brain Membranes|doi=10.1248/bpb.30.2328|pmid=18057721|journal=Biological and Pharmaceutical Bulletin|issn=0918-6158|eissn=1347-5215|oclc=27784830|date=December 2007|volume=30|issue=12|pages=2328-2333}}</ref> It also acts as a very weak, non-selective [[RIMA]] in-vitro<ref>{{cite journal|title=Studies of Monoamine Oxidase and Semicarbazide-Sensitive Amine Oxidase II. Inhibition by α-Methylated Substrate-Analogue Monoamines, α-Methyltryptamine, α-Methylbenzylamine and Two Enantiomers of α-Methylbenzylamine|last1=Arai|first1=Y.|last2=Toyoshima|first2=Y.|last3=Kinemuchi|first3=H.|year=1986|volume=41|issue=2|pages=191-197|doi=10.1254/jjp.41.191|journal=The Japanese Journal of Pharmacology|pmid=3747266|issn=1347-8613}}</ref> and in-vivo.<ref>{{cite journal|last1=Greig|first1=M. E.|last2=Walk|first2=R. A.|last3=Gibbons|first3=A. J.|title=The effect of three tryptamine derivatives on serotonin metabolism in vitro and in vivo|pmid=13851725|url=http://jpet.aspetjournals.org/content/127/2/110.short|journal=Journal of Pharmacology and Experimental Therapeutics|date=October 1959|volume=127|issue=2|pages=110-115|issn=0022-3565|eissn=1521-0103|oclc=1606914}}</ref>, but this is unlikely to be very significant (if at all) with common doses. | ||
==Subjective effects== | ==Subjective effects== | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
{{effects/base | |||
*'''[[Effect::Spontaneous | |{{effects/physical| | ||
*'''[[Effect::Stimulation]]''' - Regarding its effects on the physical energy levels of the user, AMT tends to be very stimulating, resulting in jaw clenching and a shakiness and unsteadiness of the hands. The stimulation encourages the user to move around, run, dance, climb or engage in physical activities. In comparison, other common psychedelics such as [[psilocybin]] are sedating and relaxed. | |||
*'''[[Effect::Spontaneous bodily sensations]]''' - AMT's "body high" can be described as an intense and constant all-encompassing sensation. In comparison to other psychedelics, this sensation does not manifest itself in the form of a continuously shifting tingling sensation that travels up and down the body spontaneously; it is instead felt like an extended, unchanging activation of every nerve ending on the body that lasts throughout the entire duration of the experience. This continuous sensation is immensely pleasurable but can become overwhelmingly intense and almost a burden at higher levels. | |||
*'''[[Effect::Difficulty urinating]]''' - A slight difficulty urinating is occasionally present. | *'''[[Effect::Difficulty urinating]]''' - A slight difficulty urinating is occasionally present. | ||
*'''[[Effect::Headaches]]''' - Many people report headaches towards the end of the experience | *'''[[Effect::Temperature regulation suppression]]''' | ||
*'''[[Effect::Headaches]]''' - Many people report headaches towards the end of the experience. | |||
*'''[[Effect::Abnormal heartbeat]]''' | |||
*'''[[Effect::Increased blood pressure]]''' | *'''[[Effect::Increased blood pressure]]''' | ||
*'''[[Effect::Increased heart rate]]''' | *'''[[Effect::Increased heart rate]]''' | ||
*'''[[Effect::Increased perspiration]]''' | *'''[[Effect::Increased perspiration]]''' | ||
*'''[[Effect::Nausea]]''' - | *'''[[Effect::Nausea]]''' - Moderate to extreme nausea is commonly reported. This either passes once the user has vomited or gradually fades by itself as the peak sets in. | ||
*'''[[Effect::Pupil dilation]]''' | *'''[[Effect::Pupil dilation]]''' | ||
}} | |||
{{effects/visual| | |||
The visual effects of AMT are mostly present only when large doses have been consumed and are proportionally mild in comparison to the intensity of its accompanying cognitive and physical effects when compared to substances such as [[LSD]] and [[psilocin]]. | The visual effects of AMT are mostly present only when large doses have been consumed and are proportionally mild in comparison to the intensity of its accompanying cognitive and physical effects when compared to substances such as [[LSD]] and [[psilocin]]. | ||
====Enhancements==== | ====Enhancements==== | ||
| Line 68: | Line 52: | ||
====Distortions==== | ====Distortions==== | ||
*'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Melting|melting]], [[Visual drifting#Flowing|flowing]], [[Visual drifting#Breathing|breathing]] and [[Visual drifting#morphing|morphing]])'' - In comparison to other [[ | *'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Melting|melting]], [[Visual drifting#Flowing|flowing]], [[Visual drifting#Breathing|breathing]] and [[Visual drifting#morphing|morphing]])'' - In comparison to other [[psychedelics]], this effect can be described as highly detailed, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style. | ||
*'''[[Effect::Symmetrical texture repetition]]''' - In comparison to more commonly used psychedelics such as [[LSD]] and [[psilocin]], this effect is significantly less intricate and complex although it is still very distinct in its presence. | *'''[[Effect::Symmetrical texture repetition]]''' - In comparison to more commonly used psychedelics such as [[LSD]] and [[psilocin]], this effect is significantly less intricate and complex although it is still very distinct in its presence. | ||
*'''[[Effect::After images]]''' | *'''[[Effect::After images]]''' | ||
| Line 76: | Line 60: | ||
====[[Effect::Geometry]]==== | ====[[Effect::Geometry]]==== | ||
The visual geometry | The visual geometry produced by aMT can be described as more similar in appearance to that of [[Psilocin]], and [[2C-E]] than [[LSD]]. At lower levels it can appear to be bland and simplistic in complexity but becomes equal regarding intricacy and depth to that of any of the classical [[psychedelics]] at higher doses. It can be comprehensively described with its [[Visual_effects:_Geometry#Variations|variations]] as intricate in complexity (at heavy dosages), abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in soft and sharp edges, small in size, fast in speed, smooth in motion, equal in round and angular corners, non-immersive in depth, and consistent in intensity. At higher dosages, the visual geometry is significantly more likely to result in states of [[Effect::8B Geometry|Level 8B]] geometry over [[8A Geometry|Level 8A]]. | ||
====Hallucinatory states==== | ====Hallucinatory states==== | ||
*'''[[Effect::Transformations]]''' | *'''[[Effect::Transformations]]''' | ||
*'''[[Effect::Internal | *'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - This particular effect is uncommon during the first half of the trip but capable of manifesting itself towards the end of the experience, particularly if sleep deprivation starts to take its toll due to the abnormally long duration. The internal hallucinations are more common within dark environments and can be comprehensively described through their [[Internal_hallucinations#Variations|variations]] as lucid in believability, fixed in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme. | ||
}} | |||
|{{effects/cognitive| | |||
In comparison to more traditional psychedelics such as [[LSD]], [[DMT]] and [[Psilocin]], the AMT head space is described as not nearly as deep, insightful or profound. | |||
The total sum of these cognitive components regardless of the setting generally includes: | |||
*'''[[Effect::Anxiety suppression]]''' | |||
*'''[[Effect::Disinhibition]]''' | |||
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This effect is consistently manifested mainly in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than with [[MDMA]]. | |||
*'''[[Effect::Analysis enhancement]]''' - This component is [[introspection]] dominant and consistently manifested only in the context of a non-social setting in which the user is alone. | |||
*'''[[Effect::Conceptual thinking]]''' | |||
*'''[[Effect::Emotion enhancement]]''' | |||
*'''[[Effect::Cognitive euphoria]]''' | |||
*'''[[Effect::Immersion enhancement]]''' | |||
*'''[[Effect::Increased music appreciation]]''' | |||
*'''[[Effect::Memory suppression]]''' | |||
**'''[[Effect::Ego death]]''' | |||
*'''[[Effect::Thought acceleration]]''' | |||
*'''[[Effect::Thought connectivity]]''' | |||
*'''[[Effect::Time distortion]]''' | |||
*'''[[Effect::Wakefulness]]''' | |||
}} | |||
{{effects/auditory| | |||
*'''[[Effect::Auditory enhancement|Enhancements]]''' | *'''[[Effect::Auditory enhancement|Enhancements]]''' | ||
*'''[[Effect::Auditory distortion|Distortions]]''' | *'''[[Effect::Auditory distortion|Distortions]]''' | ||
*'''[[Effect::Auditory hallucinations|Hallucinations]]''' | *'''[[Effect::Auditory hallucinations|Hallucinations]]''' | ||
}} | |||
}} | |||
===Experience reports=== | ===Experience reports=== | ||
Anecdotal reports which describe the effects of this compound within our [[experience index]] include: | Anecdotal reports which describe the effects of this compound within our [[experience index]] include: | ||
{{#ask:[[Category:Experience]][[Category:AMT]]|format=ul|Columns=1}} | {{#ask:[[Category:Experience]][[Category:AMT]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_AMT.shtml Erowid Experience Vaults: αMT] | |||
*[https://www.erowid.org/experiences/subs/exp_AMT.shtml Erowid Experience Vaults: αMT] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
{{toxicity}} | |||
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}} | {{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}} | ||
The toxicity and long-term health effects of recreational αMT use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because AMT is a [[research chemical]] with very little history of human usage. | |||
As a [[monoamine]] [[reuptake inhibitor]], αMT can be dangerous when taken in excessive doses or when combined with [[MAOIs]], [[RIMAs]], [[stimulants]] and any substance which act as a [[releasing agent]] or [[reuptake inhibitor]] of [[serotonin]] and [[dopamine]]. There is one reported death from AMT, but it is not known how much of the substance was taken.<ref name="amt2">{{cite journal|title=Fatality due to acute alpha-methyltryptamine intoxication|pmid=16105268|doi=10.1093/jat/29.5.394|date=July 1, 2005|last1=Boland|first1=D. M.|last2=Andollo|first2=W.|last3=Hime|first3=G. W.|last4=Hearn|first4=W. L.|volume=29|issue=5|pages=394-397|journal=Journal of Analytical Toxicology|issn=0146-4760|eissn=1945-2403|oclc=02942106}}</ref> Erowid states that they have received "a handful of unverifiable reports of hospitalization after high-dose (over 60 mg oral) AMT ingestion."<ref name="amt"></ref> | |||
It is worth noting that αMT's | It is worth noting that αMT's analog [[αET]] has been shown to produce long-lasting serotonergic neurotoxicity at very high doses.<ref>{{cite journal|last1=Huang|first1=X. M.|last2=Johnson|first2=M. P.|last3=Nichols|first3=D. E.|author-link3=David E. Nichols|pmid=1722753|doi=10.1016/0014-2999(91)90686-k |title=Reduction in brain serotonin markers by α-ethyltryptamine (Monase)|volume=200|issue=1|date=July 23, 1991|pages=187-190|journal=European Journal of Pharmacology|issn=0014-2999|eissn=1879-0712|oclc=01568459}}</ref> It is possible that AMT could cause the same neurotoxicity at high dosages or with repeated long-term use. | ||
Anecdotal reports suggest that there are no negative health effects attributed to simply trying aMT by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. | |||
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance. | It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance. | ||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||
AMT is [[Addiction potential:: | AMT is considered to be [[Addiction potential::moderately habit-forming]]. | ||
Tolerance to the effects of αMT | Tolerance to the effects of αMT is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::14 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 month]] to be back at baseline (in the absence of further consumption). AMT presents cross-tolerance with [[Cross-tolerance::all [[psychedelics]]]], meaning that after the consumption of αMT all psychedelics will have a reduced effect. | ||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
Deaths from αMT are rare<ref name="amt"> | Deaths from αMT are rare<ref name="amt"></ref><ref name="amt2"></ref> but, as a powerful [[monoamine]] [[reuptake inhibitor]] (MRI), injury could occur when excessive doses are taken or when it is taken with substances such as [[MAOIs]], [[RIMAs]], [[stimulants]] and any substance which act as a [[releasing agent]] or [[reuptake inhibitor]] of [[neurotransmitters]] such as [[serotonin]] and [[dopamine]].<ref>{{cite journal|title=Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity|last1=Gillman|first1=P. K.|pmid=16051647|doi=10.1093/bja/aei210|url=https://bjanaesthesia.org/article/S0007-0912(17)34956-5/fulltext|volume=95|issue=4|pages=434-441|journal=British Journal of Anaesthesia|issn=0007-0912|eissn=1471-6771|oclc=01537271|date=October 1, 2005}}</ref> | ||
*'''[[UncertainInteraction::Alcohol]]''' - aMT has a broad mechanism of action in the brain and so does alcohol so the combination can be unpredictable | |||
*'''[[UncertainInteraction::Caffeine]]''' - High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating the combination may cause some physical discomfort. | |||
*'''[[ | *'''[[UncertainInteraction::Cannabis]]''' | ||
*'''[[ | *'''[[DangerousInteraction::2C-T-x]]''' | ||
*'''[[ | *'''[[DangerousInteraction::2C-x]]''' | ||
*'''[[ | *'''[[DangerousInteraction::5-MeO-xxT]]''' | ||
*'''[[ | *'''[[DangerousInteraction::Amphetamines]]''' | ||
*'''[[ | *'''[[DangerousInteraction::Cocaine]]''' | ||
*'''[[ | *'''[[DangerousInteraction::DOx]]''' | ||
*'''[[ | *'''[[DangerousInteraction::DXM]]''' | ||
*'''[[ | *'''[[DangerousInteraction::MAOIs]]''' - aMT is an MAOI on its own. Using enzyme inhibitors can greatly reduce predictability of effects. | ||
*'''[[ | *'''[[DangerousInteraction::MDMA]]''' | ||
*'''[[ | *'''[[DangerousInteraction::Mescaline]]''' | ||
*'''[[ | *'''[[DangerousInteraction::MXE]]''' | ||
*'''[[ | *'''[[DangerousInteraction::25x-NBOMe]]''' | ||
*'''[[DangerousInteraction::PCP]]''' | |||
*'''[[ | *'''[[DangerousInteraction::SSRIs]]''' | ||
*'''[[ | *'''[[DangerousInteraction::Tramadol]]''' | ||
*'''[[ | |||
*'''[[ | ==Legal status== | ||
*'''[[ | As of 2014, AMT is not under international control.<ref name="who.int">{{cite conference|conference=Expert Committee on Drug Dependence|volume=Thirty-sixth Meeting|location=Geneva|date=June 2014|title=Alpha-methyltryptamine (AMT): Critical Review Report|id=Agenda item 4.20|publisher=World Health Organization (WHO)|url=https://www.who.int/medicines/areas/quality_safety/4_20_Review.pdf|pages=14-15}}</ref> | ||
*''' | |||
*''' | *'''Australia''': AMT is illegal to possess, produce and sell. It is controlled as an analogue of 5-MeO-AMT, which is a schedule 9 controlled substance.<ref name="who.int" /> | ||
*'''[ | *'''Austria''': AMT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).<ref name="who.int" /> | ||
*'''[[ | *'''Canada''': Canada has no mention of this substance in the Controlled substances and Substances Act.<ref>{{cite web|url=http://isomerdesign.com/Cdsa/schedule.php?structure=C|title=Controlled Drugs and Substances Act - Schedule I|access-date=July 18, 2020|publisher=Isomer Design}}</ref> | ||
*''' | *'''China''': As of October 2015 AMT is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=国家食品药品监督管理总局 [China Food and Drug Administration] | date=September 27, 2015 | language=Chinese | accessdate=October 1, 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | archive-date=October 1, 2015}}</ref> | ||
*''' | *'''Denmark ''':In 2010, the Danish Minister for the Interior and Health placed AMT to their lists of controlled substances (List B).<ref name="who.int" /> | ||
*''' | *'''Germany''': AMT is controlled under Anlage I BtMG (Narcotics Act, Schedule I)<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Betäubungsmittelgesetz (BtMG) Anlage I|trans-title=Narcotics Act (BtMG) Schedule I|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> as of January 31, 1993.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl192s2483.pdf|title=Vierte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag [Federal Gazette]|language=de|work=Bundesgesetzblatt Jahrgang 1992 Teil I Nr. 61|page=1058|publication-date=December 31, 1992|date=December 23, 1992|eissn=0344-7634}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Betäubungsmittelgesetz (BtMG) § 29|trans-title=Narcotics Act (BtMG) § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> | ||
*'''[ | *'''Greece''': AMT is illegal to possess, produce and sell under law 4139/2013. <ref>{{Citation | title=Νόμος 4139/2013 - ΦΕΚ A-74/20-3-2013 (Κωδικοποιημένος) | url=https://www.e-nomothesia.gr/kat-narkotika/n-4139-2013.html}}</ref> | ||
|} | *'''Hungary''':AMT was controlled on the Schedule C list in Hungary in 2013.<ref name="who.int" /> | ||
*'''Japan''': AMT is illegal to possess, produce and sell.{{citation needed}} | |||
*'''Latvia''': AMT is a Schedule I drug.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref> | |||
*'''Lithuania''': As of 2012, AMT is controlled as a tryptamine derivative under the 1st list of Narcotic Drugs and Psychotropic Substances which prohibites its use for medical purposes.<ref name="who.int" /> | |||
*'''Russia''': AMT is illegal to possess, produce and sell.{{citation needed}} | |||
*'''Slovakia''': AMT was placed on the List of Hazardous Substances in Annex, § 2 in Slovakia in 2013.<ref name="who.int" /> | |||
*'''Slovenia''': AMT appeared on the Decree on Classification of Illicit Drugs in 2013.<ref name="who.int" /> | |||
*'''Spain''': AMT is controlled according to the Act on the Prohibition of Certain Goods.<ref name="who.int" /> | |||
*'''Sweden''': AMT is illegal to possess, produce and sell.<ref>{{cite web|title=Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor|url=http://www.notisum.se/rnp/sls/sfs/20050026.pdf|language=sv|access-date=July 18, 2020|publication-date=October 16, 2019}}</ref> | |||
*'''Switzerland''': AMT, along with AET are controlled substances specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | |||
*'''United Kingdom''': AMT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=January 7, 2020|publisher=UK Government}}</ref> | |||
*'''United States''': αMT is a Schedule I drug. On April 4, 2003, the United States DEA added both 5-MeO-DiPT and αMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.<ref>{{cite web|archive-url=https://web.archive.org/web/20160128045930/http://webcache.googleusercontent.com/search?q=cache:http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf|url=http://webcache.googleusercontent.com/search?q=cache:http://www.deadiversion.usdoj.gov/drug_chem_info/amt.pdf|access-date=July 18, 2020|title=ALPHA-METHYLTRYPTAMINE|publisher=Drug Enforcement Administration|date=April 2013|archive-date=January 28, 2016}}</ref> | |||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Research chemical]] | *[[Research chemical]] | ||
| Line 162: | Line 176: | ||
==External links== | ==External links== | ||
*[http://en.wikipedia.org/wiki/Alpha-Methyltryptamine AMT (Wikipedia)] | *[http://en.wikipedia.org/wiki/Alpha-Methyltryptamine AMT (Wikipedia)] | ||
*[https://www.erowid.org/chemicals/amt/amt.shtml AMT (Erowid)] | *[https://www.erowid.org/chemicals/amt/amt.shtml AMT (Erowid Vault)] | ||
*[https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=48 AMT (TiHKAL)] | *[https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=48 AMT (TiHKAL)] | ||
*[http://www.bluelight.org/vb/threads/344033-The-Big-and-Dandy-AMT-Thread-2nd-incarnation AMT (Bluelight)] | ===Discussion=== | ||
*[http://www.bluelight.org/vb/threads/344033-The-Big-and-Dandy-AMT-Thread-2nd-incarnation The Big and Dandy AMT Thread - 2nd incarnation (Bluelight)] | |||
==References== | ==References== | ||
{{reflist|2}} | |||
[[Category:Substance]] | |||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category: | [[Category:Hallucinogen]] | ||
[[Category:Psychedelic]] | [[Category:Psychedelic]] | ||
[[Category:Entactogen]] | [[Category:Entactogen]] | ||
[[Category:Tryptamine]] | |||
{{#set:Featured=true | {{#set:Featured=true | ||